BIIB
NASDAQ · Biotechnology
Biogen Inc
$191.06
+1.88 (+0.99%)
Financial Highlights (FY 2026)
Revenue
9.87B
Net Income
1.29B
Gross Margin
76.0%
Profit Margin
13.1%
Rev Growth
-0.9%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 76.0% | 76.0% | 41.9% | 41.9% |
| Operating Margin | 17.4% | 15.7% | 21.3% | 24.2% |
| Profit Margin | 13.1% | 12.4% | 24.1% | 25.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.87B | 9.96B | 3.09B | 3.69B |
| Gross Profit | 7.50B | 7.57B | 1.29B | 1.55B |
| Operating Income | 1.72B | 1.56B | 657.08M | 892.05M |
| Net Income | 1.29B | 1.17B | 745.08M | 945.00M |
| Gross Margin | 76.0% | 76.0% | 41.9% | 41.9% |
| Operating Margin | 17.4% | 15.7% | 21.3% | 24.2% |
| Profit Margin | 13.1% | 12.4% | 24.1% | 25.6% |
| Rev Growth | -0.9% | -0.9% | +20.7% | -0.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.41B | 3.41B | 12.71B | 12.61B |
| Total Equity | 9.91B | 9.91B | 12.45B | 11.58B |
| D/E Ratio | 0.34 | 0.34 | 1.02 | 1.09 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 2.54B | 2.44B | 1.15B | 1.28B |
| Free Cash Flow | — | — | 775.19M | 835.69M |